Plain-English translation of NCT05641688 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new brain imaging scan called PET can accurately detect harmful protein buildup (called tau) in the brains of people with Alzheimer's disease. The scan results will be compared to actual brain tissue samples examined after death to see how accurate the imaging is. This helps doctors understand if this medication scan could be a reliable tool for diagnosing Alzheimer's disease during a person's lifetime.
Right now, Alzheimer's disease can only be definitively diagnosed by examining brain tissue after death. This trial exists to see whether this new imaging scan could give doctors a way to detect Alzheimer's changes while patients are still alive, which could help with earlier diagnosis and treatment.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a PET brain imaging scan with the study medication to look for signs of Alzheimer's disease. The scan involves lying still in an imaging machine for a period of time. You will also need to agree to donate your brain for examination after you pass away, so researchers can compare what the scan showed to what is actually found in your brain tissue. This comparison helps the research team understand how accurate the imaging scan truly is.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States